IRCT201304302575N4
Completed
未知
Comparison the results of adding Recombinant luteinizing hormone (rLH) to Recombinant folicle stimulating hormone (r-FSH) with r-FSH alone on pregnancy rate in normoresponder infertile patients in assisted reproductive technolog treatment
Yazd research and clinical center for infertility0 sites40 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yazd research and clinical center for infertility
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •inclusion criteria: infertile women younger than 35 years, serum day 3 Folicle stimulating hormone (FSH) levels \<10, male infertility or unexplained infertility and body mass index (BMI) less than 30\.
- •exclusion criteria: azoospermia, uterine myoma, mild endometriosis, Hydrosalpinx, history of previous In vitrofertilization (IVF) (successful or unsuccessful), history of endocrine diseases such as diabetes or thyroid disorders and patients who had hysteroscopic surgery due to intrauterine lesions such as uterine sub\-mucosal myoma or intrauterine adhesions
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
ior ®EPOCIM as a cardioprotective agent in the surgery of rheumatic valvular disease.Rheumatic valvular diseaseRPCEC00000165Center of Molecular Immunology (CIM), Havana30
Completed
Not Applicable
A randomised dose comparison study of recombinant human growth hormone effects on metabolism markers in children with growth hormone (GH) deficiencyutritional, Metabolic, Endocrine: Growth hormone deficiencyNutritional, Metabolic, EndocrineGrowth hormone deficiencyISRCTN44127724Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)5
Completed
Not Applicable
rinary follicle stimulating hormone (FSH) usage in in vitro fertilisation (IVF) cyclesPrimary infertilityPregnancy and ChildbirthInfertilityISRCTN55462029Bahceci Women Health Care Center (Turkey)200
Completed
Phase 3
Comparing the effects of recombinant form of human PTH and the Brand type (Forteo) in improving Bone Mineral Density in patients having osteoporosisOsteoporosis.Osteoporosis with and without pathological fractureM81.0, M80IRCT138810121414N5Cinagen biotechnology92
Completed
Not Applicable
Does the addition of Recombinant Luteinising Hormone (recLH) (Luveris) to a regimen of Recombinant Follicle Stimulating Hormone (recFSH) (Gonal-F) and Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide) improve ovarian response and implantation rates in patients age >35 years undergoing in vitro fertilisation (IVF)/embryo transfer (ET)?SubfertilityUrological and Genital DiseasesFemale infertilityISRCTN10841210VU University Medical Centre (VUMC) (Netherlands)600